310 related articles for article (PubMed ID: 33886338)
21. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.
Zhang H; Xia X
Hum Vaccin Immunother; 2021 Sep; 17(9):2995-2998. PubMed ID: 33945399
[TBL] [Abstract][Full Text] [Related]
22. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
23. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
24. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger.
Hu Y; Lin L; Chen J; Maruyama A; Tian H; Chen X
Biomaterials; 2020 Sep; 252():120114. PubMed ID: 32422491
[TBL] [Abstract][Full Text] [Related]
25. An antigen self-assembled and dendritic cell-targeted nanovaccine for enhanced immunity against cancer.
Zhang Y; Jiang M; Du G; Zhong X; He C; Qin M; Hou Y; Liu R; Sun X
Acta Pharm Sin B; 2023 Aug; 13(8):3518-3534. PubMed ID: 37655327
[TBL] [Abstract][Full Text] [Related]
26. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
27. A Universal Cyclodextrin-Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity.
Mao J; Jin Z; Rui X; Li L; Hou C; Leng X; Bi X; Chen Z; Chen Y; Wang J
Adv Healthc Mater; 2023 Oct; 12(27):e2301099. PubMed ID: 37602523
[TBL] [Abstract][Full Text] [Related]
28. Fused Cytomembrane-Camouflaged Nanoparticles for Tumor-Specific Immunotherapy.
Ji P; Deng XC; Jin XK; Zhang SM; Wang JW; Feng J; Chen WH; Zhang XZ
Adv Healthc Mater; 2023 Sep; 12(23):e2300323. PubMed ID: 37212324
[TBL] [Abstract][Full Text] [Related]
29. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
Liu M; Feng Y; Lu Y; Huang R; Zhang Y; Zhao Y; Mo R
Sci Adv; 2024 Mar; 10(11):eadk2444. PubMed ID: 38478602
[TBL] [Abstract][Full Text] [Related]
30. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
31. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
32. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
33. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
34. A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy.
Lu Z; Zhang Y; Wang Y; Tan GH; Huang FY; Cao R; He N; Zhang L
J Control Release; 2021 Apr; 332():245-259. PubMed ID: 33647430
[TBL] [Abstract][Full Text] [Related]
35. Clickable amino acid derivative tuned self-assembly of antigen and adjuvant for cancer immunotherapy.
He X; Yang L; Su H; Lin S; Qi D; Chen H; Qu Y; Liu L; Feng X
J Control Release; 2021 Sep; 337():306-316. PubMed ID: 34311025
[TBL] [Abstract][Full Text] [Related]
36. DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
Zhu G; Liu Y; Yang X; Kim YH; Zhang H; Jia R; Liao HS; Jin A; Lin J; Aronova M; Leapman R; Nie Z; Niu G; Chen X
Nanoscale; 2016 Mar; 8(12):6684-92. PubMed ID: 26947116
[TBL] [Abstract][Full Text] [Related]
37. Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy.
Gao ZL; Xu W; Zheng SJ; Duan QJ; Liu R; Du JZ
Nano Lett; 2023 Mar; 23(5):1904-1913. PubMed ID: 36801829
[TBL] [Abstract][Full Text] [Related]
38. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
39. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
[TBL] [Abstract][Full Text] [Related]
40. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
